VIVUS Reports Third Quarter 2015 Financial Results MOUNTAIN

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
VIVUS Reports Third Quarter 2015 Financial Results

MOUNTAIN VIEW, CA --(Marketwired - November 04, 2015) - VIVUS, Inc. ( NASDAQ : VVUS ) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the third quarter ended September 30, 2015.

"The U.S. market for branded anti-obesity pharmacotherapeutics continues to develop at a substantially lower rate than expected, held in check by a number of factors," said Seth H. Z. Fischer, CEO. "We watched this trend closely while controlling our costs during the first half of 2015. In August 2015, we reduced our Qsymia sales force to fifty territories and further streamlined our headquarters staff. The objective of this restructuring was to align our resources with obesity market realities and the opportunity as it currently exists, and to bring VIVUS closer to achieving neutral or positive operating cash flows by year-end 2016. Going forward, we will continue to monitor market conditions for any positive developments with physicians, payors, and patients that may indicate an increased investment is warranted."

Mr. Fischer continued, "We are working with leading cardiovascular outcome trial experts in planning substantial revisions to the original design and execution of the FDA-required Qsymia cardiovascular outcomes trial (CVOT) known as AQCLAIM, with the goal of reducing costs while also fulfilling the requirement of further demonstrating the long-term cardiovascular safety of Qsymia. We met earlier this year with the FDA to provide a CVOT program update. This dialog is ongoing, and we are committed to involving the FDA in reviewing alternative proposals that will satisfy the requirements."

VIVUS is actively pursuing a commercial partnership for avanafil in Latin America, and the Company plans to make an announcement as soon as an alliance is secured. VIVUS is pleased with the plans being executed currently by its STENDRA ® and SPEDRA ™ commercialization partners to promote the 15-minute onset of action data as a key component of their promotional campaigns.

Third Quarter 2015 Financial Results

Total revenue was $24.9 million in the current quarter, compared to $33.9 million in the third quarter of 2014. Net product revenue was $14.0 million from sales of Qsymia in the current quarter, compared to $12.5 million in the third quarter of 2014. Under our commercialization agreements for STENDRA® or SPEDRA™, we recognized $10.0 million in supply revenue in the current quarter, compared to $5.3 million in the third quarter of 2014. We also recognized $0.9 million in royalty revenue in the current quarter, compared to $1.1 million in the third quarter of 2014.

Approximately 146,000 Qsymia prescriptions were dispensed in the current quarter, compared to 140,000 in the third quarter of 2014.

Total cost of goods sold, excluding inventory impairment, was $11.8 million in the current quarter, compared to $7.3 million in the third quarter of 2014. The increase was due primarily to the cost of STENDRA supply in proportion to the increase in supply revenue.

Total selling, general and administrative expense was $17.1 million in the current quarter, compared to $27.8 million in the third quarter of 2014. Selling and marketing expense for the commercialization of Qsymia totaled $11.0 million in the current quarter, compared to $18.4 million in the third quarter of 2014. The total decrease was due primarily to the realignment of our sales force, refinement of our marketing and promotional programs, and continued cost cutting initiatives.

Total research and development expense was $1.5 million in the current quarter, compared to $2.6 million in the third quarter of 2014. The fluctuation was due primarily to the timing of clinical projects.

Charges incurred for severance were approximately $2.5 million in the current quarter, related to our restructuring plan initiated in July 2015. Annual savings from this restructuring are expected to be approximately $14.4 million beginning in year 2016.

Net loss was $16.1 million, or $0.15 net loss per share, in the current quarter, compared to a net loss of $15.8 million, or $0.15 net loss per share, in the third quarter of 2014.

Cash, Cash Equivalents and Available-for-Sale Securities

Cash, cash equivalents and available-for-sale securities (collectively cash) totaled $251.1 million at September 30, 2015, as compared to $299.6 million at December 31, 2014. The decrease was due primarily to cash used in operating activities and repayment of debt.

Recent Business Update

In July 2015, we initiated a specialty sales force co-promotion pilot program with Kadmon Corporation intended to introduce Qsymia to liver disease specialists. This pilot program will be evaluated at year-end 2015.

Note to Investors

As previously announced, VIVUS will hold a conference call and an audio webcast to discuss the third quarter ended September 30, 2015 financial results today, November 4, 2015, beginning at 4:30PM Eastern Time. Investors may listen to this call by dialing toll-free (877) 359-2916 in the U.S. and (224) 357-2386 from outside the U.S. A webcast replay will be available for 30 days and may be accessed at http://ir.vivus.com/ .

About Qsymia

Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia ® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.

About Avanafil

STENDRA ® (avanafil) is approved in the U.S. by the FDA for the treatment of erectile dysfunction. Auxilium Pharmaceuticals, Inc. has exclusive marketing rights to STENDRA in the U.S. and Canada. In January 2015, Auxilium was purchased by Endo International, plc., or Endo.

STENDRA is available through retail and mail order pharmacies. Endo currently offers programs that help patients with out-of-pocket costs.

SPEDRA ™ , the trade name for avanafil in the EU, is approved by the EMA for the treatment of erectile dysfunction in the EU. VIVUS has granted an exclusive license to the Menarini Group through its subsidiary Berlin-Chemie AG to commercialize and promote SPEDRA for the treatment of erectile dysfunction in over 40 European countries plus Australia and New Zealand.

VIVUS has granted an exclusive license to Sanofi to commercialize avanafil in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia.

Avanafil is licensed from Mitsubishi Tanabe Pharma Corporation (MTPC). VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian-Pacific Rim countries. VIVUS is in discussions with other parties for the commercialization rights to its remaining territories.

For more information about STENDRA, please visit www.Stendra.com .

Important Safety Information

STENDRA ® (avanafil) is prescribed to treat erectile dysfunction (ED).

Do not take STENDRA if you take nitrates, often prescribed for chest pain, as this may cause a sudden, unsafe drop in blood pressure.

Discuss your general health status with your healthcare provider to ensure that you are healthy enough to engage in sexual activity. If you experience chest pain, nausea, or any other discomforts during sex, seek immediate medical help.

STENDRA may affect the way other medicines work. Tell your healthcare provider if you take any of the following; medicines called HIV protease inhibitors, such as ritonavir (Norvir ® ), indinavir (Crixivan ® ), saquinavir (Fortavase ® or Invirase ® ) or atazanavir (Reyataz ® ); some types of oral antifungal medicines, such as ketoconazole (Nizoral ® ), and itraconazole (Sporanox ® ); or some types of antibiotics, such as clarithromycin (Biaxin ® ), telithromycin (Ketek ® ), or erythromycin.

In the rare event of an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury.

In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, including STENDRA) reported a sudden decrease or loss of vision. It is not possible to determine whether these events are related directly to these medicines or to other factors. If you experience sudden decrease or loss of vision, stop taking PDE5 inhibitors, including STENDRA, and call a doctor right away.

Sudden decrease or loss of hearing has been rarely reported in people taking PDE5 inhibitors, including STENDRA. It is not possible to determine whether these events are related directly to the PDE5 inhibitors or to other factors. If you experience sudden decrease or loss of hearing, stop taking STENDRA and contact a doctor right away. If you have prostate problems or high blood pressure for which you take medicines called alpha blockers or other anti-hypertensives, your doctor may start you on a lower dose of STENDRA.

Drinking too much alcohol when taking STENDRA may lead to headache, dizziness, and lower blood pressure.

STENDRA in combination with other treatments for ED is not recommended.

STENDRA does not protect against sexually transmitted diseases, including HIV.

The most common side effects of STENDRA are headache, flushing, runny nose and congestion.

Please see full patient prescribing information for STENDRA (50 mg, 100 mg, 200 mg) tablets.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com .

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks, uncertainties and other factors, including risks and uncertainties related to our ability to eliminate expenses and reduce our headcount and fully realize the benefits from a corporate restructuring to achieve neutral or positive operating cash flows by year-end 2016, including the timing thereof; risks and uncertainties related to the impact of lower annual net cost savings than currently expected; risks and uncertainties related to the impact of a corporate restructuring on our business and unanticipated charges not currently contemplated that may occur as a result of a corporate restructuring; risks and uncertainties related to our ability to accurately forecast Qsymia demand and inventory requirements, including the impact of a corporate restructuring on our future sales forecast and inventory; risks and uncertainties related to our ability to work with leading cardiovascular outcome trial experts in planning substantial revisions to the original design and execution of the CVOT with the goal of reducing costs and obtaining FDA agreement that the revised CVOT would fulfill the requirement of demonstrating the long-term cardiovascular safety of Qsymia; and risks and uncertainties related to our ability to successfully complete on acceptable terms, and on a timely basis, avanafil partnering discussions for other territories under our license with MTPC in which we do not have a commercial collaboration, including Latin America. These risks and uncertainties could cause actual results to differ materially from those referred to in these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2014 as filed on February 25, 2015 and as amended by the Form 10-K/A filed on April 30, 2015, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.

   
VIVUS, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(In thousands, except per share data)  
(Unaudited)  
                         
    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2015     2014     2015     2014  
Revenue:                                
  Net product revenue   $ 14,011     $ 12,454     $ 40,652     $ 32,575  
  License and milestone revenue     -       15,070       11,574       38,614  
  Supply revenue     10,056       5,300       26,651       18,336  
  Royalty revenue     869       1,053       1,210       2,924  
    Total revenue     24,936       33,877       80,087       92,449  
                                 
Operating expenses:                                
  Cost of goods sold     11,765       7,268       31,531       23,816  
  Selling, general and administrative     17,129       27,828       65,730       84,703  
  Research and development     1,532       2,574       6,825       11,083  
  Inventory impairment and other non-recurring charges     2,539       4,119       32,061       6,173  
    Total operating expenses     32,965       41,789       136,147       125,775  
                                 
Loss from operations     (8,029 )     (7,912 )     (56,060 )     (33,326 )
                                 
Interest expense and other expense, net     8,076       8,135       24,851       24,534  
Loss before income taxes     (16,105 )     (16,047 )     (80,911 )     (57,860 )
Provision for (benefit from) income taxes     1       (222 )     13       (660 )
  Net loss   $ (16,106 )   $ (15,825 )   $ (80,924 )   $ (57,200 )
                                 
Basic and diluted net loss per share   $ (0.15 )   $ (0.15 )   $ (0.78 )   $ (0.55 )
Shares used in per share computation:                                
  Basic and diluted     104,014       103,477       103,950       103,373  
                                   
                                   
                                   
VIVUS, INC.  
CONDENSED CONSOLIDATED BALANCE SHEETS  
(In thousands )  
             
    September 30,     December 31,  
    2015     2014*  
ASSETS   (Unaudited)        
Current assets:                
  Cash and cash equivalents   $ 79,496     $ 83,174  
  Available-for-sale securities     171,591       216,397  
  Accounts receivable, net     14,894       11,595  
  Inventories     9,228       34,447  
  Prepaid expenses and other assets     9,640       12,824  
    Total current assets     284,849       358,437  
Property and equipment, net     1,121       1,346  
Non-current assets     5,288       7,155  
    Total assets   $ 291,258     $ 366,938  
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current liabilities:                
  Accounts payable   $ 7,522     $ 10,430  
  Accrued and other liabilities     14,821       17,037  
  Deferred revenue     21,978       19,445  
  Current portion of long-term debt     15,080       10,459  
    Total current liabilities     59,401       57,371  
  Long-term debt, net of current portion     219,166       217,324  
  Deferred revenue, net of current portion     7,124       8,876  
  Non-current accrued and other liabilities     692       849  
    Total liabilities     286,383       284,420  
Commitments and contingencies                
Stockholders' equity:                
  Common stock and additional paid-in capital     828,952       825,795  
  Accumulated other comprehensive (loss) income     96       (28 )
  Accumulated deficit     (824,173 )     (743,249 )
    Total stockholders' equity     4,875       82,518  
    Total liabilities and stockholders' equity   $ 291,258     $ 366,938  
                     
 
* The Condensed Consolidated Balance Sheet at December 31, 2014 has been derived from the Company's audited financial statements at that date.
 

VIVUS, Inc. Dana B. Shinbaum Corporate Development & Investor Relations shinbaum@vivus.com 650-934-5200 Investor Relations: The Trout Group Brian Korb Managing Director bkorb@troutgroup.com 646-378-2923

Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 134

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 118

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Lyft Upgraded to Buy: Insights for Future Growth Potential

Updated Category News Views 292

Lyft's Upgrade by Benchmark: A Closer Look Benchmark analysts have recently upgraded Lyft (NASDAQ: LYFT) from Hold to Buy, highlighting what's described as "significant optionality" for the rideshare company. This decision comes despite the heightened competition from major players like Tesla and Waymo, indicating confidence in Lyft's capability to navigate potential...

Continue Reading
LiveOne Board Changes Amid Expansion and Financial Growth

Updated Category News Views 120

LiveOne Announces Departure of Board Member LiveOne, Inc. (NASDAQ:LVO) has recently made headlines in the retail-eating sector with the announcement of Craig Foster's resignation from its board of directors. Foster, who also contributed to the Audit Committee and Nominating and Corporate Governance Committee, stepped down to focus on his other professional commitments....

Continue Reading
Concorde International Group's Remarkable 80% After-Hours Surge

Updated Category News Views 429

Concorde International Group's Stock Surge Explained Concorde International Group Ltd. (NASDAQ: CIGL) has captured attention in the stock market after experiencing an impressive 80.16% increase during after-hours trading, reaching a price of $4.63. Investors are buzzing and speculating about what led to this dramatic leap. Exciting New Equity Incentive Plan Announced The...

Continue Reading
Celebrating the Legacy of Dr. Iain Douglas-Hamilton

Updated Category News Views 301

Special Screenings of A Life Among Elephants In a remarkable celebration of conservation, special screenings of the inspiring film A Life Among Elephants will honor the legacy of Dr. Iain Douglas-Hamilton. This film encapsulates the essence of his lifelong dedication to elephant conservation, portraying not only the threats faced by these majestic creatures but also the...

Continue Reading
Saudi Arabia Launches Major SME Report at Biban24 Event

Updated Category News Views 75

Saudi Arabia Presents Key Economic Insights at Biban24 As Saudi Arabia continues its path toward achieving ambitious Vision 2030 objectives, Monsha'at, the authority dedicated to small and medium enterprises (SMEs), is hosting Biban24. This significant event, designed to promote entrepreneurship and growth opportunities, brings together global entrepreneurs and investors...

Continue Reading